Wednesday, May 28, 2025

Cinnarizine CAS 298-57-7

 Cinnarizine CAS 298-57-7 Wholesale & Bulk

Cinnarizine CAS 298-57-7 is a vasodilation drug. Cinnarizine has a dilating effect on the smooth muscle of blood vessels and has an antagonism effect on various vasoconstrictive substances such as 5-serotonin, epinephrine, peptides, superchargedins, etc., which can relieve vascular spasms. It can significantly increase cerebral blood flow, can significantly improve brain circulation and coronary circulation. Its effect duration is also longer, and a variety of vascular active substances have an inhibitory effect, can alleviate vascular spasms, prevent blood vessels brittle. Without affecting heart rate and oxygen consumption, cinnarizine can increase coronary blood flow and cardiac output.

 

Cinnarizine is mainly used for the treatment of cerebrovascular disorders and peripheral vascular diseases such as cerebral embolism, cerebral thrombosis, cerebral arteriosclerosis, cerebral circulatory insufficiency caused by hypertension, cerebral hemorrhage and subarachnoid hemorrhage, and sequelae of brain trauma. It is also effective for psychostrepia and coronary arteriosclerosis caused by cerebral circulation disorders. It can also be used to treat nausea, vomiting and motion sickness caused by inner ear vertigo and other labyrinthine disorders.

 

Specifications of Cinnarizine CAS 298-57-7

ITEMS

SPECIFICATIONS

RESULT

Description

White or whitish crystalline odorless powder

White crystalline powder

Melting point

117-120℃

118.0-118.5℃

Alkalinity

R E D

R E D

Chloride

Comply

Comply

Loss on drying

≤0.5%

0.2%

Sulphated ash

≤0.1%

0.05%

Heavy metals

≤20ppm

Comply

Assay

≥98.0% C26H28N2 (calculated on dry substance)

98.80

 

Parameters of Cinnarizine CAS 298-57-7

Product parameters

Cas number:

298-57-7

Appearance:

White crystalline powder

Purity:

98%min

Package details:

25kg/drum

Brand:

Fortunachem

 

For more information about active ingredient in pharmaceutical, please feel free to contact us!



No comments:

Post a Comment